An observational study in Lymphedema, sponsored by Stanford University. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2023-11-22.
Sponsored by Stanford University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lymphedema by Stanford University — 4 open to participants now, 4 under way, none of them phase 3. Lymphedema · Stanford University.
Among the 12 studies in Lymphedema by Stanford University, this one is one of 3 that started in 2009, is one of 4 observational ones, and was the 3rd registered.
529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.
Browse Lymphedema studies →4 of the 12 studies in Lymphedema by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18–75 · Women only
Stanford University · Sites in United States
Ages 18–75 · Women only
Stanford University
Healthy volunteers
By country, each count listing its studies:
Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 103 across 145 observational studies indexed under Lymphedema.
Median enrollment 50 across the 8 interventional studies, 515 across the 4 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
2 of the studies in Lymphedema by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05825157Stanford UniversityEvaluation of Combination Therapy for Upper Extremity Lymphedema | 2027-01-01 |
| NCT05366699Stanford UniversityLYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Lymphedema by Stanford University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the International Lymphatic Disease and Lymphedema Patient Registry and Biorepository is to collect health information in order to study the disease classification, natural history, and impact of Lymphatic Disease, Lymphedema and Related Disorders and its treatments and medical outcomes.
This project represents the inauguration of an International Patient Registry for Lymphatic Diseases. This project will be completed through an affiliation with the Lymphatic Education \& Research Network, a non-profit organization whose mission is to promote research and the development of new therapies for patients with lymphatic diseases, including lymphedema. The registry will provide researchers with much-needed clinical data to study the impact of diseases of the lymphatic system, in order to develop improved treatments and find a cure for lymphatic diseases, lymphedema, and related disorders. The establishment of this initiative is a major step forward in research for direct study of groups of patients with lymphatic disease. In the future, this project will be able to be linked with a biorepository, in which tissue and blood samples derived from patients will be made available for research into human disease states. An international patient registry and tissue/cell bank program paves the way for future clinical trials of experimental drugs and therapies designed to treat lymphatic disease in human subjects.
Participants (national and international participants) with the presence of lymphatic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
prevalence of lymphatic disease
Time frame: 15 years
socioeconomic impact of lymphatic disease
The data in the registry will be utilized to determine the financial impact of requisite diagnostic and treatment interventions and will be analyzed to consider the relative contribution of third-party payer participation in the cost of care. The financial impact of disease and treatment will be addressed through the financial data entered by registry participants.
Time frame: 15 years
Plan to share: Undecided — grouped data may be shared
The record gives a start of Mar 2009, a primary completion of Dec 2024 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.